Sarepta Therapeutics

Yahoo Finance • 4 days ago

Duchenne Muscular Dystrophy Drugs Market Global Forecast 2025-2032: Sarepta, Pfizer, BioMarin, Roche, Bayer, Solid Biosciences, Cytokinetics, and NS Pharma Drive Innovation and Commercial Expansion

Company Logo The Duchenne Muscular Dystrophy Drugs Market presents opportunities in advanced genetic therapies, digital health, and adaptive models amid rising global demand. Strategic alliances, resilient supply chains, and localized str... Full story

Yahoo Finance • 7 days ago

Advanced Viral Delivery Systems Revolutionizing Gene Therapy for Neurological Disorders

Dublin, Oct. 06, 2025 (GLOBE NEWSWIRE) -- The "Gene Therapy on Neurological Diseases Market Report 2025" has been added to ResearchAndMarkets.com's offering. The gene therapy on neurological diseases market size has grown rapidly in... Full story

Yahoo Finance • 11 days ago

Stocks making the biggest moves midday: Starbucks, FICO, Acadia Healthcare & more

Check out the companies making the biggest moves midday: Acadia Healthcare — The healthcare stock jumped about 7% after investors Khrom Capital filed to push the company to explore strategic alternatives. Acadia shares are down 33% year to... Full story

Yahoo Finance • 13 days ago

Aurinia responds after top FDA official’s comment on lead drug

[US Food and Drug Administration (FDA)] Aurinia Pharmaceuticals (NASDAQ:AUPH [https://seekingalpha.com/symbol/AUPH]) traded ~7% higher in the premarket on Tuesday after the company responded to a comment made by a top FDA regulator regard... Full story

Yahoo Finance • 16 days ago

Roche Shares Dip 4% as Pharma Tariff Decision Looms: What Is the Stock Really Worth?

If you own Roche Holding stock or are weighing whether now is the right time to step in, you are not alone. The recent price action has certainly caught the eye of investors. Roche’s shares closed at 253.5, down 4.4% over the past week and... Full story

Yahoo Finance • 21 days ago

Stocks making the biggest moves midday: Oracle, Apple, Metsera, Compass, Kenvue and more

Check out the companies making headlines in midday trading : Better Home & Finance Holding — The mortgage lender briefly soared as much as 176% Monday after hedge fund manager Eric Jackson in a social media post on X called Better Home "th... Full story

Yahoo Finance • 21 days ago

Stocks making the biggest premarket moves: Metsera, Compass, Kenvue, Fox & more

Check out the companies making headlines before the opening bell : Metsera , Pfizer — The weight-loss drugmaker soared 60% after an announcement it would be bought by Pfizer for $4.9 billion in cash. The deal is expected to close in the fo... Full story

Yahoo Finance • last month

Vinay Prasad, back at FDA, becomes chief medical and scientific officer -- again

[Headquarters of US Food and Drug Administration (FDA)] Grandbrothers Vinay Prasad, a top US FDA official who left [https://seekingalpha.com/news/4474009-fda-vaccines-head-chief-medical-officer-vinay-prasad-departs-agency]the agency in la... Full story

Yahoo Finance • last month

Benjamin Graham Detailed Fundamental Analysis - SRPT

Below is Validea's guru fundamental report for SAREPTA THERAPEUTICS INC (SRPT). Of the 22 guru strategies we follow, SRPT rates highest using our Value Investor model based on the published strategy of Benjamin Graham. This deep value met... Full story

Yahoo Finance • last month

Regeneron Pharmaceuticals, Inc. (REGN): A Bull Case Theory

We came across a bullish thesis on Regeneron Pharmaceuticals, Inc. on Value investing subreddit by Significant-Foot3928. In this article, we will summarize the bulls’ thesis on REGN. Regeneron Pharmaceuticals, Inc.'s share was trading at $... Full story

Yahoo Finance • last month

Sarepta Therapeutics (SRPT) Fell Despite Reporting Good Results

Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Mid Cap Growth Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. Mid-cap stocks rebounded in the second quarter,... Full story

Yahoo Finance • last month

SRPT Stock Alert: Investors with Large Losses Should Contact Robbins LLP for Information About the Pending Lead Plaintiff Deadline in the Sarepta Therapeutics, Inc. Class Action

SAN DIEGO, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Sarepta Therapeutics, Inc. (NASDAQ: SRPT) securities between June 22,... Full story

Yahoo Finance • 2 months ago

Sector Update: Health Care Stocks Mixed Pre-Bell Wednesday

Health care stocks were mixed premarket Wednesday, as the Health Care Select Sector SPDR Fund (XLV) PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium... Full story

Yahoo Finance • 2 months ago

Elanco Animal Health set to join S&P MidCap 400, Sarepta to join S&P SmallCap 600

Elanco Animal Health (NYSE:ELAN [https://seekingalpha.com/symbol/ELAN]) will replace Sarepta Therapeutics (NASDAQ:SRPT [https://seekingalpha.com/symbol/SRPT]) in the S&P MidCap 400, and Sarepta Therapeutics will replace Brookline Bancorp (... Full story

Yahoo Finance • 2 months ago

Elanco Animal Health Set to Join S&P MidCap 400; Sarepta Therapeutics to Join S&P SmallCap 600

NEW YORK, Aug. 26, 2025 /PRNewswire/ -- Elanco Animal Health Inc. (NYSE: ELAN) will replace Sarepta Therapeutics Inc. (NASD: SRPT) in the S&P MidCap 400, and Sarepta Therapeutics will replace Brookline Bancorp Inc. (NASD: BRKL) in the S&P... Full story

Yahoo Finance • 2 months ago

Investors in Sarepta Therapeutics, Inc. Should Contact Levi & Korsinsky Before August 25, 2025 to Discuss Your Rights – SRPT

NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to... Full story

Yahoo Finance • 2 months ago

SAREPTA FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Sarepta Therapeutics, Inc. and Encourages Investors to Contact the Firm Before the August 25th Deadline

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Sarepta (SRPT) To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Sarepta between June 22,2... Full story

Yahoo Finance • 2 months ago

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - SRPT

NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT). Such investors are advised to contact Danielle... Full story

Yahoo Finance • 2 months ago

Mizuho maintains Sarepta Therapeutics stock rating, lowers Elevidys sales forecast

Investing.com - Mizuho maintained its Neutral rating and $19.00 price target on Sarepta Therapeutics (NASDAQ:SRPT) following the company’s second-quarter 2025 earnings report and debt refinancing. The stock, currently trading at $20.22,... Full story

Yahoo Finance • 2 months ago

SRPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

NEW YORK, Aug. 24, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sarepta Therapeutics, Inc. (“... Full story